Skip to main content
main-content

01.12.2019 | Case Report | Ausgabe 1/2019 Open Access

Diagnostic Pathology 1/2019

Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report

Zeitschrift:
Diagnostic Pathology > Ausgabe 1/2019
Autoren:
Mitsutake Yano, Daisuke Shintani, Tomomi Katoh, Mei Hamada, Kozue Ito, Eito Kozawa, Kosei Hasegawa, Masanori Yasuda

Abstract

Background

Endometrial mesonephric-like adenocarcinomas exhibit classical histologic features of mesonephric carcinoma; however, it remains unclear whether these tumors represent mesonephric (Wolffian) carcinoma or endometrioid (Müllerian) carcinomas that closely mimic mesonephric carcinoma.

Case presentation

A 32-year-old Japanese primigravida presented with atypical vaginal bleeding. An endometrial biopsy suggested low-grade endometrioid carcinoma, and she was administered medroxyprogesterone acetate. Her tumor recurred 6 years later, and she underwent hysterectomy, salpingo-oophorectomy, and omentectomy, at which point she was diagnosed with mesonephric-like adenocarcinoma of the uterine endometrium. Retrospective pathological review of the initial biopsy confirmed coexisting low-grade endometrioid carcinoma and mesonephric-like adenocarcinoma of the uterine endometrium. On immunohistochemistry, the endometrioid carcinoma component was diffuse positive for estrogen and progesterone receptors but negative for thyroid transcription factor 1. However, the mesonephric-like adenocarcinoma component exhibited a mixture of estrogen receptor- and thyroid transcription factor 1-positive cells within the same glands.

Conclusions

We encountered a patient with coexisting endometrial mesonephric-like adenocarcinoma and low-grade endometrioid carcinoma, which was treated using medroxyprogesterone acetate therapy, resulting in recurrence of mesonephric-like adenocarcinoma alone. These clinicopathological findings support the prevailing notions that mesonephric-like adenocarcinoma is a Müllerian adenocarcinoma exhibiting mesonephric differentiation.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

Diagnostic Pathology 1/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie

14.04.2021 | Schwerpunkt: Neue WHO-Klassifikationen und Digitales Lernen | Ausgabe 3/2021

Digitale Lehre im Fach Pathologie

06.04.2021 | Nierenkarzinom | Schwerpunkt: Neue WHO-Klassifikationen und Digitales Lernen | Ausgabe 3/2021

Histologische Subtypen des Nierenzellkarzinoms

Übersicht und neue Entwicklungen

06.04.2021 | Sarkome | Schwerpunkt: Neue WHO-Klassifikationen und Digitales Lernen | Ausgabe 3/2021

Neues in der aktuellen WHO-Klassifikation (2020) für Weichgewebssarkome